Literature DB >> 20067378

Metastatic phenotype is regulated by estrogen in thyroid cells.

Shilpi Rajoria1, Robert Suriano, Arulkumaran Shanmugam, Yushan Lisa Wilson, Stimson P Schantz, Jan Geliebter, Raj K Tiwari.   

Abstract

BACKGROUND: Over 200 million people worldwide are affected by thyroid proliferative diseases, including cancer, adenoma, and goiter, annually. The incidences of thyroid malignancies are three to four times higher in women, suggesting the possible involvement of estrogen. Based on this observed sex bias, we hypothesize that estrogen modulates the growth and metastatic propensity of thyroid cancer cells.
METHODS: In this study, two thyroid cell lines (Nthy-ori 3-1 and BCPAP) were evaluated for the presence of estrogen receptor (ER) by Western blot analysis and estrogen responsiveness by using a cell proliferation assay. In addition, the effect of estradiol (E(2)) on modulation of metastatic phenotype was determined by using in vitro adhesion, migration, and invasion assays.
RESULTS: Thyroid cells expressed a functionally active ER-alpha and ER-beta as evidenced by 50-150% enhancement of proliferation in the presence of E(2). E(2) also enhanced adhesion, migration, and invasion of thyroid cells in an in vitro experimental model system that, based on our results, is modulated by beta-catenin.
CONCLUSION: Our data provide evidence that the higher incidence of thyroid cancer in women is potentially attributed to the presence of a functional ER that participates in cellular processes contributing to enhanced mitogenic, migratory, and invasive properties of thyroid cells. These findings will enable and foster the possible development of antiestrogenic therapy targeting invasion and migration, thus affecting metastatic propensity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20067378      PMCID: PMC2833180          DOI: 10.1089/thy.2009.0296

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  42 in total

1.  Thyroid cancer: is the incidence still increasing?

Authors:  Nicole C Hodgson; Jaclyn Button; Carmen C Solorzano
Journal:  Ann Surg Oncol       Date:  2004-12       Impact factor: 5.344

2.  Hormone replacement therapy increases the risk of breast cancer.

Authors:  G A Colditz
Journal:  Ann N Y Acad Sci       Date:  1997-12-29       Impact factor: 5.691

3.  3,3'-Diindolylmethane, a cruciferous vegetable derived synthetic anti-proliferative compound in thyroid disease.

Authors:  Kiranmayi Tadi; Yushan Chang; Badithe T Ashok; Yuangen Chen; Augustine Moscatello; Steven D Schaefer; Stimsom P Schantz; Anthony J Policastro; Jan Geliebter; Raj K Tiwari
Journal:  Biochem Biophys Res Commun       Date:  2005-10-03       Impact factor: 3.575

4.  Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells.

Authors:  Veena Vijayanathan; Sripriya Venkiteswaran; Sandhya K Nair; Arti Verma; T J Thomas; Bao Ting Zhu; Thresia Thomas
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

5.  3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer.

Authors:  Venkata P S Garikapaty; Badithe T Ashok; Kiranmayi Tadi; Abraham Mittelman; Raj K Tiwari
Journal:  Biochem Biophys Res Commun       Date:  2005-12-20       Impact factor: 3.575

6.  Differences in glycosylation patterns of heat shock protein, gp96: implications for prostate cancer prevention.

Authors:  Robert Suriano; Salil K Ghosh; Badithe T Ashok; Abraham Mittelman; Yuangen Chen; Asesh Banerjee; Raj K Tiwari
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

7.  Female thyroid cancer: the role of reproductive and hormonal factors in Switzerland.

Authors:  F Levi; S Franceschi; C Gulie; E Negri; C La Vecchia
Journal:  Oncology       Date:  1993 Jul-Aug       Impact factor: 2.935

8.  17-Beta-estradiol inhibits transforming-growth-factor-beta-induced MCF-7 cell migration by Smad3-repression.

Authors:  Daniela Malek; Ronald Gust; Burkhard Kleuser
Journal:  Eur J Pharmacol       Date:  2006-02-23       Impact factor: 4.432

Review 9.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia.

Authors:  Tetsuo Kondo; Shereen Ezzat; Sylvia L Asa
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

Review 10.  Is there a role of autoimmunity in implantation failure after in-vitro fertilization?

Authors:  Amy M Cline; William H Kutteh
Journal:  Curr Opin Obstet Gynecol       Date:  2009-06       Impact factor: 1.927

View more
  63 in total

1.  Estrogen is increased in male cholangiocarcinoma patients' serum and stimulates invasion in cholangiocarcinoma cell lines in vitro.

Authors:  Taweewun Hunsawong; Ekapot Singsuksawat; Nuannapa In-chon; Watinee Chawengrattanachot; Chanitra Thuwajit; Banchob Sripa; Anucha Paupairoj; Siri Chau-in; Peti Thuwajit
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-03       Impact factor: 4.553

2.  High prevalence of breast cancer in patients with benign thyroid diseases.

Authors:  I Muller; A Pinchera; E Fiore; V Belardi; V Rosellini; E Giustarini; C Giani
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

Review 3.  The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis.

Authors:  Sarah M Nielsen; Michael G White; Susan Hong; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Swati A Kulkarni; Olufunmilayo I Olopade; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02       Impact factor: 4.254

4.  Parity and Risk of Thyroid Cancer: a Population-Based Study in Lithuania.

Authors:  L Zabuliene; D Jasilionis; E Miseikyte-Kaubriene; R Stukas; A Kaceniene; G Smailyte
Journal:  Horm Cancer       Date:  2017-09-15       Impact factor: 3.869

5.  Benign breast and gynecologic conditions, reproductive and hormonal factors, and risk of thyroid cancer.

Authors:  Melissa Z Braganza; Amy Berrington de González; Sara J Schonfeld; Nicolas Wentzensen; Alina V Brenner; Cari M Kitahara
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-21

6.  Estrogen and thyroid cancer is a stem affair: A preliminary study.

Authors:  Mariangela Zane; Carmelo Parello; Gianmaria Pennelli; Danyelle M Townsend; Stefano Merigliano; Marco Boscaro; Antonio Toniato; Giovannella Baggio; Maria Rosa Pelizzo; Domenico Rubello; Isabella Merante Boschin
Journal:  Biomed Pharmacother       Date:  2016-11-26       Impact factor: 6.529

Review 7.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

8.  Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.

Authors:  V G Antico-Arciuch; M Dima; X-H Liao; S Refetoff; A Di Cristofano
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

9.  Hysterectomy, Oophorectomy, and Risk of Thyroid Cancer.

Authors:  Juhua Luo; Michael Hendryx; JoAnn E Manson; XiaoYun Liang; Karen L Margolis
Journal:  J Clin Endocrinol Metab       Date:  2016-07-26       Impact factor: 5.958

10.  Breastfeeding and thyroid cancer risk in women: A dose-response meta-analysis of epidemiological studies.

Authors:  Xingyang Yi; Jingjing Zhu; Xiao Zhu; Guang Jian Liu; Lang Wu
Journal:  Clin Nutr       Date:  2015-12-17       Impact factor: 7.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.